Grace Therapeutics, Inc. Common Stock

GRCENASDAQUSD
2.29 USD
0.07 (3.15%)AT CLOSE (11:59 AM EDT)
2.29
0.01 (0.22%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
2.29
0.01 (0.22%)
🔴Market: CLOSED

Shares of Grace Therapeutics, Inc. Common Stock (GRCE) are trading at $2.29. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, GRCE appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Sep 14, 2026.

Open?$2.21
High?$2.32
Low?$2.21
Prev. Close?$2.22
Volume?48.3K
Avg. Volume?174.6K
VWAP?$2.28
Rel. Volume?0.28x
Bid / Ask
Bid?$1.95 × 100
Ask?$2.60 × 100
Spread?$0.65
Midpoint?$2.28
Valuation & Ratios
Market Cap?46.7M
Shares Out?21.0M
Float?15.1M
Float %?71.6%
P/E Ratio?N/A
P/B Ratio?0.97
EPS?-$0.96
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Employees
5
Market Cap
46.7M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-04-26
Address
103 CARNEGIE CENTER
PRINCETON, NJ 08540
Phone: 609-322-1602
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+1/3)
Medium-Term (Wave)? Bullish(+2/3)
Short-Term (Ripple)? Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
28
Piotroski F-Score?0/9Weak
Altman Z-Score?6.96Safe
Confidence?36%Very Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?10.53%High
Short Interest?1.6M
Days to Cover?18.3
Free Float15.1M
Avg Daily Volume86.7K
Settlement Date2026-08-31
Financial Health
Current Ratio?11.47Strong
Quick Ratio?11.47Strong
Cash Ratio?11.00Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A
P/B?
Peers
100
S&P
97
0.97CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
S&P
97
-3.2CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
S&P
3
-41.9%WEAK
ROA?
S&P
3
-40.4%WEAK
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$32.9M
Fundamentals ratios updated end of day